Furthermore, the current study provides a putative signaling pathway that could be a therapeutic target for diabetic complications; that is, because HIF-1α was beneficial for the integrity of the sural nerve, a combination of HIF-1α overexpression and CD40 inhibition could be a therapeutic strategy for improving microvascular and nerve integrity in diabetic neuropathy. The gene discussed is HIF1A; the disease is diabetic neuropathy.